SpyGlass Pharma, Inc. Deferred Federal Income Tax Expense (Benefit)
SpyGlass Pharma, Inc. (SGP) reported Deferred Federal Income Tax Expense (Benefit) of -$8.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-03-26
- SpyGlass Pharma, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was -$8.70M.
- SpyGlass Pharma, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was -$5.67M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$8.70M 10-K · filed 2026-03-26 |
| 2024-12-31 | -$5.67M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |